Halted Phase III Clinical Trial For Alzheimer’s Shows Renewed Promise
Pharmaceutical company Biogen announced they plan to file for US marketing approval of the potential Alzheimer’s drug, aducanumab. Aducanumab is an antibody designed to target…
Read more...